 | |
| Clinical data | |
|---|---|
| Other names | SAL067 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H19FN6O |
| Molar mass | 342.378 g·mol−1 |
Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP. [1] [2] [3] In a phase 3 trial it showed similar results as alogliptin. [4]
Inhibitors of dipeptidyl peptidase 4 are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2.
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin.
Romance of the Three Kingdoms is a Chinese television series adapted from the classical 14th century novel of the same title by Luo Guanzhong. The series was produced by China Central Television (CCTV) and was first aired on the network in 1994. It spanned a total of 84 episodes, each approximately 45 minutes long. One of the most expensive television series produced at the time, the project cost 170 million yuan. It was completed over four years and involved over 400,000 cast and crew members, including divisions of the People's Liberation Army from the Beijing, Nanjing and Chengdu military regions. Some of the dialogue spoken by characters was adapted directly from the novel. Extensive battle scenes, such as the battles of Guandu, Red Cliffs and Xiaoting, were also live-acted.
Alogliptin, sold under the brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.
Three Kingdoms is a 2010 Chinese television series based on the events in the late Eastern Han dynasty and the Three Kingdoms period. The plot is adapted from the 14th century historical novel Romance of the Three Kingdoms and other stories about the Three Kingdoms period. Directed by Gao Xixi, the series had a budget of over 160 million RMB and took five years of pre-production work. Shooting of the series commenced in October 2008, and it was released in China in May 2010.
Dipeptidyl peptidase-4 inhibitors are enzyme inhibitors that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). They are used in the treatment of type 2 diabetes mellitus. Inhibition of the DPP-4 enzyme prolongs and enhances the activity of incretins that play an important role in insulin secretion and blood glucose control regulation. Type 2 diabetes mellitus is a chronic metabolic disease that results from inability of the β-cells in the pancreas to secrete sufficient amounts of insulin to meet the body's needs. Insulin resistance and increased hepatic glucose production can also play a role by increasing the body's demand for insulin. Current treatments, other than insulin supplementation, are sometimes not sufficient to achieve control and may cause undesirable side effects, such as weight gain and hypoglycemia. In recent years, new drugs have been developed, based on continuing research into the mechanism of insulin production and regulation of the metabolism of sugar in the body. The enzyme DPP-4 has been found to play a significant role.
All Men Are Brothers is a 2011 Chinese television series adapted from Shi Nai'an's 14th century novel Water Margin, one of the Four Great Classical Novels of Chinese literature. The series is directed by Kuk Kwok-leung and features cast members from mainland China, Taiwan and Hong Kong. The series was first broadcast on 8TV in March 2011 in Malaysia.
The Han Triumph, also known as Wind Ode, is a Chinese television series based on historical events in the early Han dynasty, beginning with the founding of the dynasty by Liu Bang after his triumph over Xiang Yu, and the events leading to the reign of Liu Heng. Directed by Huang Jianzhong, the series starred Ray Lui, Wang Ji, Liu Mu, Zhang Guangbei, Chen Wei and Li Qingxiang in the leading roles. It was first broadcast on CCTV-8 in China on 17 December 2011.
Justice Bao is a Chinese TV series starring producer Jin Chao-chun as the Song dynasty official Bao Zheng. The series ran for 3 seasons from 2010 to 2012. In addition to Jin, Kenny Ho, Fan Hung-hsuan and Lung Lung again reprise their iconic roles from the 1993 Taiwanese hit Justice Pao and the 2008 Chinese series Justice Bao.
Amazing Detective Di Renjie 2, also known as Shen Tan Di Renjie 2, is the second installment in a four-season Chinese television series based on gong'an detective stories related to Di Renjie, a Tang dynasty magistrate and statesman. Written and directed by Qian Yanqiu, the series starred Liang Guanhua as the titular protagonist, and was first broadcast on CCTV-8 on 20 November 2006, two years after the first season. It was followed by Amazing Detective Di Renjie 3 in 2008, and Mad Detective Di Renjie in 2010. The series was released in the United States on March 21, 2018 on Toku.
The Romance of the Condor Heroes is a 2014–15 Chinese television series produced by Yu Zheng and adapted from Jin Yong's novel The Return of the Condor Heroes, with additional material from the preceding novel, The Legend of the Condor Heroes. It stars Chen Xiao and Michelle Chen in the lead roles. The series was first broadcast on Hunan TV from 3 December 2014 to 11 March 2015.
Su Dongpo is a 2012 Chinese historical TV series produced by China Central Television. It was first shown in 2012, although it was filmed in 2007.
Gosogliptin is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It was discovered and developed through Phase 1 and Phase 2 by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available. Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described. A cost efficient route has been published. Other studies including Phase 3 studies were conducted in Russia. It is approved for use in Russia.
Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers.
Cofrogliptin is a long-acting DPP4 inhibitor dosed once every two weeks.
Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.
Janagliflozin is an SGLT2 inhibitor developed by Sihuan Pharmaceutical. It is approved in China for the treatment of type 2 diabetes.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |